Cholesterol drug showdown: which version works best?
NCT ID NCT07422285
First seen Feb 23, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This early-stage study compares two forms of the cholesterol-lowering drug evolocumab in 400 healthy adults aged 18 to 60. Participants receive a single injection of one version, and researchers measure how much drug gets into the blood and how long it stays. The goal is to see if the two versions are absorbed similarly, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fortrea Clinical Research Unit - Dallas
RECRUITINGDallas, Texas, 75247, United States
-
Fortrea Clinical Research Unit - Daytona Beach
RECRUITINGDaytona Beach, Florida, 32117-5116, United States
-
Fortrea Clinical Research Unit Inc. - Madison
RECRUITINGMadison, Wisconsin, 53704-2526, United States
-
Ohio Clinical Trials, Inc.
RECRUITINGColumbus, Ohio, 43212, United States
-
QPS Bio-Kinetic
RECRUITINGSpringfield, Missouri, 65802-4842, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
evolocumab (a cholesterol-lowering drug)
What this could lead to
If successful, this study could help confirm that two manufacturing versions of evolocumab are absorbed similarly, supporting future supply flexibility.
What could go wrong
This is an early-phase trial in healthy people, not patients. It measures drug levels in the blood, not health outcomes, so results may not predict real-world effectiveness or safety.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.